NDI Notifications Are Not Swept Aside As New Drugs – FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA’s rejection of PharmaRoth Labs’ Sucanon NDI notifications included a suggestion that the firm try the investigational new drug pathway, but is not a sign of a growing trend at the agency.